JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Închisă

SectorSănătate

185.78 1.25

Rezumat

Modificarea prețului

24h

Curent

Minim

185.31

Maxim

185.87

Indicatori cheie

By Trading Economics

Venit

27M

330M

Vânzări

104M

5.3B

P/E

Medie Sector

33.913

38.156

EPS

3.35

Randament dividend

2.23

Marjă de profit

6.259

Angajați

70,000

EBITDA

93M

546M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+8.32% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

2.23%

2.50%

Următoarele câștiguri

7 aug. 2025

Data viitoare de dividende

30 sept. 2025

Următoarea dată ex-dividende

8 sept. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-15B

50B

Deschiderea anterioară

184.53

Închiderea anterioară

185.78

Sentimentul știrilor

By Acuity

16%

84%

20 / 375 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Becton Dickinson and Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 iul. 2025, 14:26 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 iul. 2025, 11:08 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 iul. 2025, 10:37 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

1 mai 2025, 11:18 UTC

Câștiguri

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

15 iul. 2025, 18:32 UTC

Achiziții, Fuziuni, Preluări

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 iul. 2025, 18:31 UTC

Achiziții, Fuziuni, Preluări

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 iul. 2025, 16:12 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 iul. 2025, 15:06 UTC

Achiziții, Fuziuni, Preluări

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 iul. 2025, 14:11 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 iul. 2025, 10:53 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 iul. 2025, 10:22 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 iul. 2025, 10:22 UTC

Achiziții, Fuziuni, Preluări

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 iul. 2025, 10:22 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 iul. 2025, 10:21 UTC

Achiziții, Fuziuni, Preluări

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 iul. 2025, 10:20 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 iul. 2025, 10:19 UTC

Achiziții, Fuziuni, Preluări

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 iul. 2025, 10:19 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 iul. 2025, 10:18 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 iul. 2025, 10:18 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 iul. 2025, 10:17 UTC

Achiziții, Fuziuni, Preluări

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 iul. 2025, 10:16 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 iul. 2025, 10:16 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14 iul. 2025, 10:15 UTC

Achiziții, Fuziuni, Preluări

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14 iul. 2025, 10:15 UTC

Achiziții, Fuziuni, Preluări

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

1 mai 2025, 10:33 UTC

Câștiguri

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 mai 2025, 10:33 UTC

Câștiguri

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 mai 2025, 10:32 UTC

Câștiguri

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 mai 2025, 10:32 UTC

Câștiguri

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 mai 2025, 10:31 UTC

Câștiguri

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 mai 2025, 10:31 UTC

Câștiguri

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Comparație

Modificare preț

Becton Dickinson and Co Așteptări

Obiectiv de preț

By TipRanks

8.32% sus

Prognoză pe 12 luni

Medie 200.73 USD  8.32%

Maxim 255 USD

Minim 172 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBecton Dickinson and Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

13 ratings

4

Cumpărare

9

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

167 / 206.99Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

20 / 375 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.